1-3 of 3
Miquel Gomez
Close
Sort by
Journal Articles

Usefulness of NT-Probnp Levels and Fresco Cardiovascular Risk Scale for Prediction of Myocardiotoxicity Induced By Anthracyclines in Patients with Diffuse Large B-Cell Lymphoma

Mariana Paola Ferraro, MD, Eva Gimeno, MD PhD, Miquel Gomez, Francesc Garcia-Pallarols, Silvia Perez, Blanca Sanchez-Gonzalez, MD PhD, Laia Martinez, Elena Torres, Eugenia Abella, MD PhD, Roberto Elosua, Josep Comín, Antonio Salar, MD PhD
Journal: Blood
Blood (2016) 128 (22): 925.
https://doi.org/10.1182/blood.V128.22.925.925
Published: 2016
Journal Articles

Modified-CHOP with Reduced Dose of Non-Pegylated Liposomal Doxorubicin ± Rituximab in First Line Treatment for Elderly Patients with Aggressive Lymphoma Non Suitables for Standard Chemotherapy.

Eva Gimeno, Blanca Sánchez, Alberto Alvarez, Carme Pedro, Eugenia Abella, Miquel Gomez, Silvia Saumell, Josep Comin, Carles Besses, Antonio Salar
Journal: Blood
Blood (2009) 114 (22): 4752.
https://doi.org/10.1182/blood.V114.22.4752.4752
Published: 2009
Journal Articles

Reduced Dose of Non-Pegylated Liposomal Doxorrubicin with Cyclophosphamide, Vincristine and Prednisone ± Rituximab for Elderly Patients with Aggressive Lymphoma Non Candidates to Standard Chemotherapy.

Eva Gimeno, Alberto Alvarez, Carme Pedro, Eugenia Abella, Miquel Gomez, Josep Comin, Carles Besses, Antonio Salar
Journal: Blood
Blood (2007) 110 (11): 4464.
https://doi.org/10.1182/blood.V110.11.4464.4464
Published: 2007